Drug Target Review

AUGUST 29, 2024

However, these treatments will eventually fail for the majority of patients, so there is a strong need for better CAR therapies. How might the CD5 knockout approach impact the treatment of other types of cancers beyond T-cell lymphoma?

Therapies 59

Therapies Treatment Engineering Molecular Biology 59

Drug Target Review

JANUARY 25, 2024

These findings offer a novel strategy for developing targeted treatments for triple-negative breast cancer, which currently has no approved options. The team also observed that the drug prevented in vitro cancer stem cells from self-renewing, which is a characteristic of aggressive cancer cells that supports treatment resistance.

Treatment 105

Treatment Clinical Trials Science Research 105

Drug Hunter

JUNE 5, 2023

Glecaprevir, or ABT-493, was approved in combination with pibrentasvir (Mavyret) for the treatment of Hepatitis C (HCV) in 2017. RCM in the Medicinal Chemistry of Pacritinib Pacritinib, a kinase inhibitor approved in 2022 for treatment of myelofibrosis, was also synthesized with an RCM in its med.

Process Chemistry 206

Process Chemistry Drugs Production Clinical Development 206

National Institute on Drug Abuse: Nora's Blog

FEBRUARY 8, 2023

Pregnant People With Substance Use Disorders Need Treatment, Not Criminalization mfleming Wed, 02/08/2023 - 15:33 Nora's Blog February 15, 2023 Image ©Getty Images/ Caia Image This blog was also published in STAT on February 8, 2023. People seeking treatment for addictions face additional obstacles, especially if they have children.

Treatment 52

Treatment Doctors Research Science 52

The Pharma Data

DECEMBER 17, 2020

18, 2020 /PRNewswire/ — Camurus AB (NASDAQ STO: CAMX) announced today that the Swiss agency for therapeutic products, Swissmedic, has approved weekly and monthly Buvidal ® prolonged release buprenorphine for the treatment of opioid dependence in adults and adolescents from 16 years of age. LUND, Sweden , Dec. About Buvidal.

Treatment 52

Treatment Clinical Trials International Pharmaceutical Companies 52

FDA Law Blog: Biosimilars

DECEMBER 4, 2023

A prescription not issued in the usual course of professional treatment or in legitimate, authorized research is not a prescription within the meaning of the CSA and the pharmacist knowingly filling it, along with the prescriber issuing it, is subject to penalties. 21 U.S.C. § 829; 21 C.F.R. Complaint ¶ 55. Complaint ¶ 58. Complaint ¶ 59.

Pharmacy 139

Pharmacy Government Treatment Compliance 139

Drug Target Review

JULY 9, 2024

Bowel cancer is the fourth most common cancer in the UK, accounting for 11 percent of all new cancer cases from 2017 to 2019 1 , and is the second most common cause of cancer death in the UK, accounting for 10 percent of all cancer deaths in the same time period. This study was published in Nature Genetics.

Regulations 105

Regulations DNA Treatment Research 105

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

The Pharma Data

NOVEMBER 26, 2020

26, 2020 — In isolated areas of the United States, nurse practitioners are filling an important role in helping people access treatment for opioid addiction, according to a Washington State University (WSU) study. THURSDAY, Nov.

Nurses 52

Nurses Treatment Doctors Drugs 52

Drug Target Review

OCTOBER 24, 2023

Live Bacterial Products (LBPs) will provide patients with a desirable, credible, safe and effective treatment option. The human microbiome, a complex ecosystem of microorganisms residing within our bodies, has emerged as a promising frontier in the quest for innovative medical treatments.

Treatment 122

Treatment Pharmacokinetics Pharmaceuticals Trials 122

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. iii Current treatment options have limited efficacy in terms of weight loss or are often associated with adverse events. “We

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

The Pharma Data

FEBRUARY 8, 2021

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer. The recruitment period for the study spanned from December 2015 to July 2017. 3 Dual primary endpoints of the study were OS and rPFS.1 About ERLEADA ® (apalutamide).

Treatment 52

Treatment Pharmaceutical Companies Therapies Pharmaceuticals 52

Conversations in Drug Development Trends

AUGUST 10, 2023

As one of the more recent fields to emerge in the clinical space, psychedelics have gained significant traction as a potential treatment for various neuropsychiatric diseases. Psychedelic Research at Worldwide Since 2017, Worldwide Clinical Trials have supported a myriad of sponsors leading the way in psychedelic research programs.

Science 98

Science Clinical Trials Trials Clinical Research 98

Drug Target Review

AUGUST 16, 2023

Cancer remains a major global health concern, often diagnosed at advanced stages when treatment options and survival rates are limited. Suspicious findings can prompt further evaluation and definitive diagnosis, enabling timely treatment and improved patient outcomes. References 1. Jillian Phallen. DOI:10.1126/scitranslmed.aan2415

DNA 98

DNA Disease Therapies Treatment 98

The Pharma Data

FEBRUARY 22, 2021

Efanesoctocog alfa, a novel and investigational factor VIII therapy independent of von Willebrand Factor, is designed to provide near-normal factor activity levels for the majority of the week in a once-weekly prophylactic treatment regimen. Sanofi and Sobi collaborate on the development and commercialization of efanesoctocog alfa.

FDA 52

FDA Treatment Therapies International 52

Broad Institute

OCTOBER 4, 2023

AbbVie and Calico discovered the molecule, called ABBV-CLS-484 , after TIDE researchers at Broad identified the PTPN2 gene as a promising cancer immunotherapy target in 2017. It still sort of stuns me that we went from discovering a target in 2017 to testing drugs in patients starting in 2020,” Yates said.

Small Molecule 128

Small Molecule Clinical Trials Engineering Trials 128

Common Sense for Drug Policy Blog

JANUARY 4, 2024

Cost Benefit Analysis of Opioid Treatment, Syringe Service Programs, and Test & Treat "Although model projections can only provide estimates of health benefits and costs, such analyses can provide intuition around critical mechanisms and assumptions to inform decision making. Published 2017 May 24. 2017;14(5):e1002312.

Treatment 52

Treatment Therapies Drugs 52

The Pharma Data

APRIL 7, 2022

It may also limit coverage for any future approved treatment in the class. When additional data from this new class of treatments become available, Biogen urges CMS to reconsider today’s decision for all FDA-approved amyloid-beta targeting therapies. ADUHELM is indicated for the treatment of Alzheimer’s disease.

Treatment 52

Treatment Therapies Disease FDA Approval 52

New Drug Approvals

NOVEMBER 13, 2023

WO 2017/208267A1, WO 2020/250133 Al and WO 2022/024072A1, which are hereby incorporated by reference, disclose methods of use of the compound of Formula I for the treatment of Parkinson’s disease, synucleinopathies and Alzheimer’s disease (AD) respectively. amcrasto@amcrasto /////////// Ref [1].

Treatment 62

Treatment Disease Therapies Production 62

Alta Sciences

MARCH 4, 2025

Despite having a final FDA guidance issued in 2017 , evolving drug development and treatment modalities continue to prompt important dialogue to adapt existing methods. One example is the recent interest in psychedelics for the treatment of psychiatric disorders, including major depressive disorder.

Clinical Trials 52

Clinical Trials FDA Drug Development Trials 52

The Pharma Data

NOVEMBER 24, 2020

25, 2020 /CNW/ – On August 21, 2020 , Health Canada approved Lynparza® (olaparib), for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM- mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent (NHA).

Treatment 52

Treatment DNA Trials Therapies 52

Alta Sciences

JUNE 27, 2023

Cancer Treatments, Clinical Trials, and the Motivation to Innovate nbartlett Tue, 06/27/2023 - 20:58 Getting to the Heart of Science with Michelle Newby At the heart of science are stories—stories of courage, challenges, successes, lessons, and people. Q: What was your cancer diagnosis and was treatment options were you given?

Clinical Trials 40

Clinical Trials Trials Treatment Science 40

Drug Target Review

OCTOBER 2, 2024

Cell and gene therapies (CGTs) have made significant advancements in treating oncological diseases, with therapies like CAR-T cell treatments transforming cancer care. By correcting these mutations, gene-modifying and editing therapies hold the promise of long-term, potentially curative treatments. 2017 May 31;58(3):435-440.

Therapies 98

Therapies Disease Engineering RNA 98

Drug Target Review

OCTOBER 17, 2023

To improve its treatment, early diagnosis and appropriate therapeutic strategies are very important. Metabolic changes such as increased arginine levels could serve as biomarkers for detecting cancer at an early stage, which is essential for successful cancer treatment and patient survival. 2017 July [cited 2023 October 9]; 3(2):45-51.

Regulations 98

Regulations Therapies Treatment Disease 98

The Pharma Data

MAY 27, 2022

In the pivotal clinical study CARTITUDE-1, 98 percent of patients with relapsed or refractory multiple myeloma responded to a one-time treatment with ciltacabtagene autoleucel and 80 percent of patients who responded experienced a stringent complete response . In December 2017, Janssen Biotech, Inc.

Therapies 52

Therapies Treatment Pharmaceutical Companies Nurses 52

Drug Target Review

NOVEMBER 17, 2023

Only three of the CAR-NK studies were for the treatment of solid tumours. By themselves, the NK cells showed limited efficacy, but anti-tumour efficacy was observed with co-treatment regimens (eg, monoclonal antibodies, haematopoietic stem cell transplants, whole body irradiation) and multiple dosing (tolerated well by patients).

Therapies 118

Therapies Clinical Trials Cell Biology Trials 118

Drug Target Review

JUNE 19, 2024

Our goal is to stand on the shoulders of giants and advance this exciting and new field of medicine, so that it can deliver valuable treatments to patients. How do you envision the future of cell therapy and its potential impact on medical treatments and healthcare? SVRA) in April 2017. from May 2017 until December 2022.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Drug Target Review

NOVEMBER 17, 2023

Only three of the CAR-NK studies were for the treatment of solid tumours. By themselves, the NK cells showed limited efficacy, but anti-tumour efficacy was observed with co-treatment regimens (eg, monoclonal antibodies, haematopoietic stem cell transplants, whole body irradiation) and multiple dosing (tolerated well by patients).

Therapies 103

Therapies Clinical Trials Immune Response Trials 103

Drug Target Review

JUNE 21, 2023

4 For the treatment of rare genetic disorders especially, drugs with genetically supported targets are more than twice as likely to be approved 5 , thereby indicating genetics and genomics can empower companies to develop better drugs. 2017 Mar 29;9(383):eaag1166. Sci Transl Med. Doi: 10.1126/scitranslmed.aag1166. medRxiv; 2023.

Disease 111

Disease Clinical Trials Therapies Science 111

New Drug Approvals

OCTOBER 12, 2024

ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease. Tramiprosate was reported to inhibit Aβ42 aggregation into toxic oligomers ( Gervais et al.,

Pharmacokinetics 62

Pharmacokinetics Small Molecule Disease Licensing 62

The Pharma Data

MARCH 9, 2022

The most common treatment-emergent adverse events (>5% of participants overall) were headache, arthralgia, fall, and back pain. Dietmar Berger, MD, PhD Global Head of Development and Chief Medical Officer , Sanofi “While advances have been made in the treatment of hemophilia, unmet medical needs still exist.

Treatment 52

Treatment Pharmacokinetics Therapies FDA 52

New Drug Approvals

SEPTEMBER 13, 2024

2] Like other kappa opioid antagonists currently under clinical investigation for the treatment of major depression, its efficacy may be compromised by the countervailing activation of pro-inflammatory cytokines in microglia within the CNS. [7] 2] Aticaprant is taken by mouth. [1] nM vs. 24.0 13] [14] Occupancy was 35% for a 0.5 nM vs. 24.0

Treatment 62

Treatment Clinical Trials Pharmacokinetics Pharmaceuticals 62

Drug Target Review

OCTOBER 26, 2023

1 Adeno-associated virus (AAV) vectors are the leading platform for in vivo gene delivery for the treatment of various human diseases. The Lancet 390 , 849-860 (2017). Genome engineering and gene therapies that manipulate DNA sequences in cells have driven a biotechnological revolution over the past decade. Wang D, Tai PW, Gao G.

Engineering 105

Engineering Virus Therapies Immune Response 105

Drug Target Review

AUGUST 24, 2023

We will explore how GDF-15 impacts the tumour microenvironment and hinders the infiltration of T cells into the tumour, as well as the implications of neutralising GDF-15 to reverse its inhibitory effects and sensitise tumours to anti-PD-1 treatment. T-cell infiltration is a prerequisite for responses to checkpoint inhibitors.

Treatment 98

Treatment Therapies Clinical Development Cell Biology 98

The Pharma Data

NOVEMBER 2, 2020

adults by using blood pressure (BP) thresholds from the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7) and the 2017 American College of Cardiology-American Heart Association (ACC-AHA) BP guidelines. adults) using the 2017 ACC-AHA guideline criteria.

Pharmaceuticals 52

Pharmaceuticals Treatment Disease Research 52

Drug Target Review

APRIL 19, 2024

And so, I have been the managerial co-founder and CEO of Sibylla since 2017. This innovation opens the door to novel treatments, especially for proteins considered ‘undruggable’ in their mature forms, marking a significant stride in the field of protein degradation and pharmaceutical development.

Molecular Biology 111

Molecular Biology Research Pharmaceuticals Small Molecule 111

Advarra

JUNE 12, 2023

An IBC may also advise the IRB in assessing potential risks to the study subjects and how best to explain the unique risks of gene therapy and other genetically engineered treatments in the informed consent form (ICF). What Does an IBC Review? The post IBC vs. IRB: What’s the Difference? appeared first on Advarra.

Engineering 98

Engineering Therapies Regulations Research 98